India - inglese - Central Drugs Standard Control Organization

eli lilly - exenatide - 5mcg( mannitol,glacial acetic acid,sod.acet.) - pfs

India - inglese - Central Drugs Standard Control Organization

sun - exenatide - inj - 250mcg/ml - 1

India - inglese - Central Drugs Standard Control Organization

natco - exenatide - 5mcg(multidose vial,m-cresol 0.2%w/v) - vial

Stati Uniti - inglese - NLM (National Library of Medicine)

precision dose, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml

Stati Uniti - inglese - NLM (National Library of Medicine)

precision dose inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml - digoxin oral solution, usp is indicated for the treatment of mild to moderate heart failure. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin oral solution, usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. digoxin should not be used for the treatment of multifocal atrial tachycardia. allergy to digoxin is rare. digoxin is contraindicated in patients with a known hypersensitivity to digoxin or other forms of digitalis. digitalis glycosides, such as digoxin, are contraindicated in ventricula

Australia - inglese - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - liraglutide -

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

astrazeneca limited - dapagliflozin propanediol monohydrate 12.3mg equivalent to dapaglifozin 10mg;   - film coated tablet - 10 mg - active: dapagliflozin propanediol monohydrate 12.3mg equivalent to dapaglifozin 10mg   excipient: colloidal silicon dioxide crospovidone opadry ii yellow lactose magnesium stearate microcrystalline cellulose - monotherapy forxiga is indicated in adults with type 2 diabetes mellitus as monotherapy as an adjunct to diet and exercise in patients for whom metformin is otherwise indicated but was not tolerated. initial combination forxiga is indicated in adults with type 2 diabetes mellitus as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycaemic control when diet and exercise have failed to provide adequate glycaemic control and there are poor prospects for response to metformin monotherapy. add-on combination forxiga is indicated in adult patients with type 2 diabetes mellitus in combination with other anti-hyperglycaemic agents to improve glycaemic control, when these together with diet and exercise do not provide adequate glycaemic control. prevention of hospitalisation for heart failure forxiga is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalisation for heart. prevention of new or worsening nephropathy forxiga is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease for the prevention of new or worsening nephropathy.

Singapore - inglese - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - lixisenatide - injection, solution - 50mcg/ml - lixisenatide 50mcg/ml

Singapore - inglese - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (10mcg) lixisenatide; (20mcg) lixisenatide - injection, solution - 0.05mg/ml - (10mcg) lixisenatide 0.05mg/ml; (20mcg) lixisenatide 0.1mg/ml

Singapore - inglese - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - lixisenatide - injection, solution - 100mcg/ml - lixisenatide 100mcg/ml